Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.

Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts.

Abstract

Raloxifene reduces bone loss and prevents vertebral fractures in postmenopausal women. Its skeletal effects are mediated by estrogen receptors (ER) and their modulation of paracrine osteoblastic factors. Receptor activator of nuclear factor-kappa B ligand is essential for osteoclasts and enhances bone resorption, whereas osteoprotegerin (OPG) neutralizes receptor activator of nuclear factor-kappa B ligand. Here, we assessed the effects of raloxifene on OPG production in human osteoblasts (hOB). Raloxifene enhanced gene expression of ER-alpha and progesterone receptor. Moreover, raloxifene increased OPG mRNA levels and protein secretion by hOB in a dose- and time-dependent fashion by 2- to 4-fold with a maximum effect at 10(-7) M and after 72 h (P < 0.001). Treatment with the ER antagonist ICI 182,780 abrogated the effects of raloxifene on OPG production. Moreover, raloxifene enhanced osteoblastic differentiation markers, type 1 collagen secretion, and alkaline phosphatase activity by 3- and 2-fold, respectively (P < 0.001). In addition, raloxifene inhibited expression of the bone-resorbing cytokine IL-6 by 25-45% (P < 0.001). In conclusion, our data suggest that raloxifene stimulates OPG production and inhibits IL-6 production by hOB. Because OPG production increases with osteoblastic maturation, enhancement of OPG production by raloxifene could be related to its stimulatory effects on osteoblastic differentiation.

Overview

Integrity signals

Registry

Crossref · 10.1210/jc.2002-021877

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 42 references

Cited by

See all 118

Metadata

Authors
Viereck, V., Gründker, C., Blaschke, S., Niederkleine, B., Siggelkow, H., Frosch, K.-H., Raddatz, D., Emons, G., & Hofbauer, L. C.
Affiliations
  • University of Göttingen (DE)
  • Philipps University of Marburg (DE)
Corresponding author
Viereck, Volker
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2003-09
Volume
88
Issue
9
Pages
4206-4213
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W1980481528
Cited by
110
References
42
Citations by year
2026: 1 · 2025: 2 · 2024: 4 · 2022: 3 · 2021: 2 · 2020: 1 · 2019: 2 · 2018: 1 · 2017: 3 · 2016: 1 · 2015: 3 · 2014: 7 · 2013: 5 · 2012: 7
FWCI
3.45
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed (publishedVersion)
  • GRO (submittedVersion)
Funders
  • Eli Lilly and Company
  • Deutsche Forschungsgemeinschaft (Ho 1875/2-1)
  • Deutsche Krebshilfe
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
Keywords
raloxifene, osteoprotegerin, interleukin-6, estrogen receptor alpha, progesterone receptor, fulvestrant, osteogenic differentiation, type I collagen, alkaline phosphatase, bone resorption, RANKL, postmenopausal bone loss, selective estrogen receptor modulators
MeSH terms
Adult, Alkaline Phosphatase, Anti-Inflammatory Agents, Cells, Cultured, Dexamethasone, DNA, Dose-Response Relationship, Drug, Estrogen Antagonists, Female, Glycoproteins, Humans, Immunohistochemistry, Male, Osteoblasts, Procollagen, Receptors, Estrogen, Receptors, Progesterone, RNA, Messenger, Trabecular Meshwork, Protein Biosynthesis, Interleukin-6, Up-Regulation, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Reverse Transcriptase Polymerase Chain Reaction, Selective Estrogen Receptor Modulators, Raloxifene Hydrochloride, Estrogen Receptor alpha, Estrogen Receptor beta, Osteoprotegerin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts. https://app.cochat.ai/papers/10.1210/jc.2002-021877
The paper
Viereck, V., Gründker, C., Blaschke, S., Niederkleine, B., Siggelkow, H., Frosch, K.-H., Raddatz, D., Emons, G., & Hofbauer, L. C. (2003). Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2002-021877

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.